Palmitoleic acid {90000278}
Parent: | [ ] |
---|---|
Definition: | Palmitoleic acid |
Queue: | [ ] |
Initialisation date: | 2022-03-15 |
---|---|
Specification: | |
[ ] | |
Source: | |
[ ] |
Structural Type: | [ ] |
---|---|
Functional Type: | [ ] |
Function: | Anti-inflammatory |
Notes:
[ ]
Shared Reference Notes
- [1.1] [#Akkermansia muciniphila, #Mycobacterium tuberculosis] [#Probiotic (A. muciniphila)]
- Oral treatment of A. muciniphila or A. muciniphila-mediated palmitoleic acid strongly inhibits #Tuberculosis infection through epigenetic inhibition of tumour necrosis factor in mice infected with Mycobacterium #Tuberculosis. - [#Akkermansia muciniphila] - single-nucleotide polymorphism #rs2257167 ‘G’ allele of type I interferon receptor 1 (encoded by IFNAR1 in humans) contributes to stronger type I interferon signalling, impaired colonization and abundance of A. muciniphila, reduced palmitoleic acid production, higher levels of tumour necrosis factor, and more severe #Tuberculosis disease in humans and transgenic mice
- [1.2]
- POA significantly upregulated the transcriptional signatures of cell division and biosynthetic process of #Akkermansia muciniphila, selectively increased the growth and abundance of #Akkermansia muciniphila in gut microbiota. - - co-administration of POA with #Akkermansia muciniphila showed significant synergistic protections against #Colitis in mice.
- [#Inflamatory bowel disease] [#Anti-TNF therapy] - Dietary palmitoleic acid (POA) repaired gut mucosal barriers, reduced inflammatory cell infiltrations and expressions of TNF-α and #IL-6, and improved efficacy of anti-TNF-α therapy in both acute and chronic IBD mouse models.
References Notes
[ ]